Lv11
30 积分 2025-02-01 加入
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
4小时前
待确认
Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study
16天前
已完结
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
16天前
已完结
Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know
1个月前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
2个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
2个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
2个月前
已完结
Optimal two-stage designs for phase II clinical trials
2个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
3个月前
已完结
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
4个月前
已完结
皖公网安备34019202002308
